Comparative Pharmacology
Head-to-head clinical analysis: DAWNZERA AUTOINJECTOR versus IMPOYZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAWNZERA AUTOINJECTOR versus IMPOYZ.
DAWNZERA (AUTOINJECTOR) vs IMPOYZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DAWNZERA (autoinjector) contains epinephrine, a non-selective agonist at alpha- and beta-adrenergic receptors. It causes vasoconstriction via alpha-1 receptors, bronchodilation via beta-2 receptors, and increased heart rate and contractility via beta-1 receptors, reversing anaphylactic symptoms.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
60 mg subcutaneously once daily, administered at approximately the same time each day.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults, allowing once-daily dosing; prolonged in renal impairment.
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion of unchanged drug (approximately 60-70%) with minor biliary/fecal elimination (20-30%).
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Category C
Category C
Unknown
Unknown